InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

Current share price for NOX : $0.086 0.003 (3.37%)+

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$26 NOX Corporate Presentation FNN-Shaw&Partners Investor Event 14 Aug 2018 1:54PM $0.595 $0.086 fallen by 85.55%
$26 Change of Director's Interest Notice - GK 9 Aug 2018 9:49AM $0.585 $0.086 fallen by 85.30%
$26 Change of Director's Interest Notice - PM 9 Aug 2018 9:46AM $0.585 $0.086 fallen by 85.30%
$26 Change of Director's Interest Notice - ID 9 Aug 2018 9:39AM $0.585 $0.086 fallen by 85.30%
$26 Appendix 3B 9 Aug 2018 9:38AM $0.585 $0.086 fallen by 85.30%
$26 Interim NOX66 Radiotherapy Clinical Data 8 Aug 2018 8:41AM $0.565 $0.086 fallen by 84.78%
$26 Appendix 4C - quarterly 30 Jul 2018 10:10AM $0.580 $0.086 fallen by 85.17%
$26 Securities to be released from Escrow 10 Jul 2018 5:07PM $0.600 $0.086 fallen by 85.67%
$26 Release of DARRT-1 Preliminary Safety Data 9 Jul 2018 9:12AM $0.635 $0.086 fallen by 86.46%
$26 Pre-Clinical data confirms Radio-Enhancing potential 5 Jul 2018 9:25AM $0.640 $0.086 fallen by 86.56%
$26 Noxopharm releases Nyrada Corporate Presentation 7 Jun 2018 8:30AM $0.700 $0.086 fallen by 87.71%
$26 Noxopharm Corporate Presentation for Public Briefing 7 Jun 2018 8:29AM $0.700 $0.086 fallen by 87.71%
$26 End-of-Study Clinical Data shows benefit of NOX66 5 Jun 2018 9:48AM $0.795 $0.086 fallen by 89.18%
$26 Noxopharm 2018 Mid-Year Investor Briefings 31 May 2018 8:41AM $0.810 $0.086 fallen by 89.38%
$26 Section 708 Certificate 28 May 2018 12:45PM $0.890 $0.086 fallen by 90.34%
$26 Appendix 3B 28 May 2018 12:45PM $0.890 $0.086 fallen by 90.34%
$26 NOX to present at American Society of Clinical Oncology 22 May 2018 9:01AM $0.860 $0.086 fallen by 90%
$26 KZA: Progress Report 21 May 2018 12:17PM $0.830 $0.086 fallen by 89.64%
$26 Change in substantial holding 21 May 2018 10:25AM $0.830 $0.086 fallen by 89.64%
$26 Securities to be released from Voluntary Escrow 21 May 2018 10:21AM $0.830 $0.086 fallen by 89.64%
$26 Section 708 Certificate 21 May 2018 10:16AM $0.855 $0.086 fallen by 89.94%
$26 Appendix 3B 21 May 2018 10:14AM $0.855 $0.086 fallen by 89.94%
$26 Noxopharm 2018 Mid-Year Investor Briefings 18 May 2018 11:32AM $0.915 $0.086 fallen by 90.60%
$26 Results of Meeting 15 May 2018 11:40AM $0.940 $0.086 fallen by 90.85%
$26 NOX CEO interview updates the company's current R&D program 7 May 2018 11:34AM $0.850 $0.086 fallen by 89.88%

601 - 625 of 797 results

Page 25 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.